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Background
Therapeutic response assessment in NSCLC is funda-
mental in order to avert futile surgery and an ineffective
toxic chemotherapy. This study sought to determine the
potential of the PET response criteria over the RECIST
Criteria 1.1 in evaluating the treatment response of the
NSCLC patients.
Materials and methods
Eighteen patients (age; 60.16±5.39 years) with metastatic
NSCLC were evaluated after 4 courses of chemotherapy
and/or target therapy. [18F]-fluorodeoxyglucose with
positron-emission tomography (PET) and computed
tomography (CT) scans were subsequently used to assess
tumour response. Discrepancies between the two proce-
dures were evaluated after 4 courses of chemotherapy of
the primary tumour lesion using the Response Evaluation
Criteria in Solid Tumours (RECIST 1.1) and European
Organisation for Research and Treatment of Cancer
(EORTC) criteria evaluating CT and PET respectively.
Results
Five morphologically partial responses (PR), two mor-
phologically stable disease (SD), one morphologically
progressive disease (PD) and two morphologically
complete morphological response (CR) were correlated
with the PET metabolic response criteria respectively. Two
(PR) were evaluated as 2 complete metabolic response
(CMR). Three cases of (SD) were evaluated as 3 CMR.
Three morphologically (PD) were evaluated as 1 CR,
1 PMR and 1 SMD. There were significant difference
between the SUVmax changes; mean: 0.51± 0.29 g/ml
versus size changes; mean 0.30± 0.24 cm, p < 0.05.
Conclusion: The RECIST 1.1 and the EORTC are two
discordant methods in evaluating the therapeutic response
of the metastatic NSCLC with the potential of greater
parametric changes of the SUV in alluding changes of the
tumour metabolic landscape.
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